Report of the second dementia with Lewy body international workshop

McKeith, Ian; Perry, Elaine K.; Perry, Robert H.

doi:10.1212/wnl.53.5.902

Cited by 446 publications

(306 citation statements)

References 25 publications

Supporting

Mentioning

299

Contrasting

Unclassified

Order By: Relevance

“…The dominating protein component normally behaves as a monomeric protein, and factors causing the transition from monomeric to fibrillar states are under intense investigation. Lewy bodies and Lewy neurites, the pathological hallmarks of Parkinson's disease and dementia with Lewy bodies (2), are intraneuronal inclusions comprising ␣-synuclein-containing filaments as the major component (3,4). Mutations in the ␣-synuclein gene may elicit rare forms of early-onset Parkinson's disease (5,6).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments

Jensen

Islam²,

Kenney

et al. 2000

Journal of Biological Chemistry

133

103

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…Dementia with Lewy bodies is the second most common form of dementia next to Alzheimer's disease (2). Hence, the pathognomonic cortical Lewy bodies are common neuronal lesions, but they have been less intensely studied as compared with brainstem Lewy bodies.…”

mentioning

confidence: 99%

Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments

Jensen

Islam²,

Kenney

et al. 2000

Journal of Biological Chemistry

133

103

View full text Add to dashboard Cite

“…18 More specifically: for an AD diagnosis, the patient must have no or mild WMC, and predominant parietotemporal lobe symptoms. Frontotemporal dementia is diagnosed according to Neary et al; 19 Lewy-body dementia according to McKeith et al; 20 and primary progressive aphasia (PPA) according to Gorno-Tempini et al 21 Vascular dementia forms are either SVD or cortical vascular dementia (cVaD). Subcortical vascular dementia is diagnosed using the Erkinjuntti criteria (2000), 22 and cVaD using the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche´et l'Enseignement en Neurosciences criteria.…”

Section: Diagnostics Of Phenotypically Specific Dementia Diseasesmentioning

confidence: 99%

The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up

Wallin

Nordlund

Jonsson

et al. 2015

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

There is a need for increased nosological knowledge to enable rational trials in Alzheimer's disease (AD) and related disorders. The ongoing Gothenburg mild cognitive impairment (MCI) study is an attempt to conduct longitudinal indepth phenotyping of patients with different forms and degrees of cognitive impairment using neuropsychological, neuroimaging, and neurochemical tools. Particular attention is paid to the interplay between AD and subcortical vascular disease, the latter representing a disease entity that may cause or contribute to cognitive impairment with an effect size that may be comparable to AD. Of 664 patients enrolled between 1999 and 2013, 195 were diagnosed with subjective cognitive impairment (SCI), 274 with mild cognitive impairment (MCI), and 195 with dementia, at baseline. Of the 195 (29%) patients with dementia at baseline, 81 (42%) had AD, 27 (14%) SVD, 41 (21%) mixed type dementia (¼AD þ SVD ¼ MixD), and 46 (23%) other etiologies. After 6 years, 292 SCI/MCI patients were eligible for followup. Of these 292, 69 (24%) had converted to dementia (29 (42%) AD, 16 (23%) SVD, 15 (22%) MixD, 9 (13%) other etiologies). The study has shown that it is possible to identify not only AD but also incipient and manifest MixD/SVD in a memory clinic setting. These conditions should be taken into account in clinical trials.

show abstract

“…The final CDR rating was based on the pattern of box scores (Morris, 1993). Dementia subtyping was accomplished after the conference by the study neurologist through chart review using established criteria for probable0possible AD (McKhann et al, 1984), probable0possible vascular dementia (VaD; Chui et al, 1992), probable0possible Lewy body dementia (McKeith et al, 1999), and frontotemporal dementia (Knopman et al, 2005).…”

Section: Diagnostic Determinationmentioning

confidence: 99%

Neuropsychological strategies for detecting early dementia

Grober

Hall

Mcginn

et al. 2007

J Int Neuropsychol Soc

View full text Add to dashboard Cite

As new and more effective treatments for Alzheimer's disease (AD) emerge, the development of efficient screening strategies in educationally and racially diverse primary care settings has increased in importance. A set of candidate screening tests and an independent diagnostic assessment were administered to a sample of 318 patients treated at a geriatric primary care center. Fifty-six subjects met criteria for dementia. Exploratory analysis led to the development of three two-stage screening strategies that differed in the composition of the first stage or Rapid Dementia Screen, which is applied to all patients over the age of 65. The second stage, applied to those patients who screen positively for dementia, is accomplished with the Free and Cued Selective Reminding Test to detect memory impairment. Using clinical diagnosis as a gold standard, the strategies had high sensitivity and specificity for identifying dementia and performed better for identifying AD than non-AD dementias. Sensitivity and specificity did not differ by race or education. The strategies provide an efficient approach to screening for early dementia.

show abstract

Report of the second dementia with Lewy body international workshop

Cited by 446 publications

References 25 publications

Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments

Microtubule-associated Protein 1B Is a Component of Cortical Lewy Bodies and Binds α-Synuclein Filaments

The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up

Neuropsychological strategies for detecting early dementia

Contact Info

Product

Resources

About